{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rivaroxaban+2.5+mg", "query": { "intervention": "Rivaroxaban 2.5 mg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 127, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rivaroxaban+2.5+mg&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T05:28:42.004Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03196349", "title": "Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Venous Thromboembolism" ], "interventions": [ { "name": "Warfarin", "type": "DRUG" }, { "name": "Apixaban 2.5 MG", "type": "DRUG" }, { "name": "Rivaroxaban 10 MG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2018-08-01", "completion_date": "2019-05-01", "has_results": true, "last_update_posted_date": "2019-12-13", "last_synced_at": "2026-09-29T05:28:42.004Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03196349" }, { "nct_id": "NCT02690155", "title": "Real-world Comparative Effectiveness of Rivaroxaban Versus VKA", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Atrial Fibrillation" ], "interventions": [ { "name": "Rivaroxaban (Xarelto, BAY59-7939)", "type": "DRUG" }, { "name": "VKA (Vitamin K antagonist)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38831, "start_date": "2016-02-12", "completion_date": "2016-03-01", "has_results": false, "last_update_posted_date": "2017-04-05", "last_synced_at": "2026-09-29T05:28:42.004Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02690155" }, { "nct_id": "NCT06961630", "title": "Post-Operative Biomarker-Guided Precision Medicine For Cardiovascular Risk Reduction", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Myocardial Injury After Noncardiac Surgery" ], "interventions": [ { "name": "Rivaroxaban", "type": "DRUG" }, { "name": "Atorvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": null, "sex": "ALL", "summary": "45 Years and older" }, "enrollment_count": 50, "start_date": "2025-10-07", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-09-29T05:28:42.004Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06961630" }, { "nct_id": "NCT05907629", "title": "Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Stroke", "Intracranial Atherosclerotic Stenosis (ICAS)" ], "interventions": [ { "name": "MRI", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2024-06-24", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-09-29T05:28:42.004Z", "location_count": 28, "location_summary": "Birmingham, Alabama • Aurora, Colorado • Hartford, Connecticut + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05907629" }, { "nct_id": "NCT01729871", "title": "A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation" ], "interventions": [ { "name": "rivaroxaban", "type": "DRUG" }, { "name": "uninterrupted vitamin K antagonist (VKA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Scientific Affairs, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 253, "start_date": "2013-02", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2017-03-06", "last_synced_at": "2026-09-29T05:28:42.004Z", "location_count": 24, "location_summary": "Beverly Hills, California • Los Angeles, California • Sacramento, California + 21 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01729871" }, { "nct_id": "NCT03310021", "title": "A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bleeding" ], "interventions": [ { "name": "Andexanet alfa", "type": "BIOLOGICAL" }, { "name": "Apixaban", "type": "DRUG" }, { "name": "Rivaroxaban", "type": "DRUG" }, { "name": "Edoxaban", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Portola Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 108, "start_date": "2017-08-28", "completion_date": "2019-08-13", "has_results": true, "last_update_posted_date": "2023-02-24", "last_synced_at": "2026-09-29T05:28:42.004Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03310021" }, { "nct_id": "NCT02502396", "title": "Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer", "Deep-vein Thrombosis of the Lower and Upper Extremities", "Pulmonary Embolism", "Non-valvular Atrial Fibrillation" ], "interventions": [ { "name": "Retrospective Chart Review", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 265, "start_date": "2015-09-28", "completion_date": "2022-03-15", "has_results": false, "last_update_posted_date": "2022-03-24", "last_synced_at": "2026-09-29T05:28:42.004Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02502396" }, { "nct_id": "NCT03271450", "title": "The DARE Warfarin CER Study", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Deep Venous Thrombosis", "Pulmonary Embolism" ], "interventions": [ { "name": "Dabigatran: extended treatment (e.g at least 90 days)", "type": "DRUG" }, { "name": "Dabigatran: extended treatment (e.g at least 180 days)", "type": "DRUG" }, { "name": "Dabigatran: extended treatment (e.g at least 270 days)", "type": "DRUG" }, { "name": "Apixaban: extended treatment (e.g at least 90 days)", "type": "DRUG" }, { "name": "Apixaban: extended treatment (e.g at least 180 days)", "type": "DRUG" }, { "name": "Apixaban: extended treatment (e.g at least 270 days)", "type": "DRUG" }, { "name": "Rivaroxaban: extended treatment (e.g at least 90 days)", "type": "DRUG" }, { "name": "Rivaroxaban: extended treatment (e.g at least 180 days)", "type": "DRUG" }, { "name": "Rivaroxaban: extended treatment (e.g at least 270 days)", "type": "DRUG" }, { "name": "Edoxaban: extended treatment (e.g at least 90 days)", "type": "DRUG" }, { "name": "Edoxaban: extended treatment (e.g at least 180 days)", "type": "DRUG" }, { "name": "Edoxaban: extended treatment (e.g at least 270 days)", "type": "DRUG" }, { "name": "Warfarin: extended treatment (e.g at least 90 days)", "type": "DRUG" }, { "name": "Warfarin: extended treatment (e.g at least 180 days)", "type": "DRUG" }, { "name": "Warfarin: extended treatment (e.g at least 270 days)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 416000, "start_date": "2017-07-01", "completion_date": "2021-10-30", "has_results": false, "last_update_posted_date": "2021-06-23", "last_synced_at": "2026-09-29T05:28:42.004Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03271450" }, { "nct_id": "NCT02584660", "title": "A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Embolism" ], "interventions": [ { "name": "Rivaroxaban", "type": "DRUG" }, { "name": "Standard-of-care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Scientific Affairs, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 114, "start_date": "2015-10-15", "completion_date": "2017-03-22", "has_results": true, "last_update_posted_date": "2018-06-01", "last_synced_at": "2026-09-29T05:28:42.004Z", "location_count": 50, "location_summary": "Montgomery, Alabama • Chandler, Arizona • Phoenix, Arizona + 47 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02584660" }, { "nct_id": "NCT00559988", "title": "Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Atrial Fibrillation", "Atrial Flutter", "Stroke", "Embolism, Systemic Arterial", "Major Bleeding" ], "interventions": [ { "name": "Home Monitoring Guided OAC", "type": "DRUG" }, { "name": "Physician-Directed OAC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biotronik, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2718, "start_date": "2008-02", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2017-12-05", "last_synced_at": "2026-09-29T05:28:42.004Z", "location_count": 73, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 70 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Santa Barbara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00559988" } ] }